Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G. Levallet G, et al. Among authors: debieuvre d. Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025. Oncotarget. 2017. PMID: 28008145 Free PMC article. Clinical Trial.
Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T. Pujol JL, et al. Among authors: debieuvre d. J Natl Cancer Inst. 2001 Feb 21;93(4):300-8. doi: 10.1093/jnci/93.4.300. J Natl Cancer Inst. 2001. PMID: 11181777 Clinical Trial.
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B, Breton JL, Lemarie E, Pujol JL, Brechot JM, Zalcman G, Debieuvre D, Vaylet F, Vergnenegre A, Clouet P. Quoix E, et al. Among authors: debieuvre d. Ann Oncol. 2004 Jan;15(1):38-44. doi: 10.1093/annonc/mdh005. Ann Oncol. 2004. PMID: 14679117 Free article. Clinical Trial.
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P, Quoix E. Gervais R, et al. Among authors: debieuvre d. Ann Oncol. 2005 Jan;16(1):90-6. doi: 10.1093/annonc/mdi018. Ann Oncol. 2005. PMID: 15598944 Free article. Clinical Trial.
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF, Milleron B, Debieuvre D, Castéra D, Souquet PJ, Moro-Sibilot D, Lemarié E, Kessler R, Janicot H, Braun D, Spaeth D, Quantin X, Clary C. Pujol JL, et al. Among authors: debieuvre d. Ann Oncol. 2005 Apr;16(4):602-10. doi: 10.1093/annonc/mdi126. Epub 2005 Mar 1. Ann Oncol. 2005. PMID: 15741225 Free article. Clinical Trial.
Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Westeel V, Quoix E, Moro-Sibilot D, Mercier M, Breton JL, Debieuvre D, Richard P, Haller MA, Milleron B, Herman D, Level MC, Lebas FX, Puyraveau M, Depierre A; French Thoracic Oncology Collaborative Group (GCOT). Westeel V, et al. Among authors: debieuvre d. J Natl Cancer Inst. 2005 Apr 6;97(7):499-506. doi: 10.1093/jnci/dji096. J Natl Cancer Inst. 2005. PMID: 15812075 Clinical Trial.
131 results